Current opinion in molecular therapeutics
Curr Opin Mol Ther
· ISSN (print) 1464-8431
· 1 paper in corpus
review
2000
Abarelix (PPI-149) is a luteinizing hormone-releasing hormone (LHRH) receptor antagonist under development by Praecis, Amgen and Sanofi-Synthelabo for the potential treatment of prostate cancer, breast cancer and hormone-related disorders […